Students and postdocs

By preserving a lipid critical to cellular cleanup, Institute Scholar Monther Abu-Remaileh and team improved a severe neurodegenerative condition in both cells and mice.

CBI fellow Mikaela Ribi is one of 10 finalists chosen for Stanford’s first Three Minute Thesis competition.

Team led by Institute Scholar Christopher Barnes and Adonis Rubio has designed a series of dual or “bispecific” antibodies, which could potentially resist the evolving SARS-CoV-2.

Bertozzi and Wyss-Coray labs' findings on brain cell sugars may reveal insights into cognitive decline and Alzheimer’s, opening new treatment possibilities.

Michael Fischbach, Djenet Bousbaine, and team's findings in mice could translate into a radical, needle-free vaccination approach that would also eliminate reactions.

The fellowship, awarded by the HHMI, recognizes PhD students and their faculty advisers who are committed to advancing equity and inclusion in the sciences.

Institute Scholar Jonathan Z. Long, María Dolores Moya Garzón and team identify a new metabolic pathway that helps explain the molecular links between ketogenic diets.

Developed by Stanford undergraduates at Stanley Qi's lab, the kit brings hands-on lessons in gene-editing technology to school classrooms.

The study was led by Brad Zuchero, Justin Du Bois together with CBI student Pablo Elvira, former ChEM-H postdocs Husniye Kantarci and Erin Gray, and their collaborators.

Chaitan Khosla, Angele Sewa & team's new findings could aid the development of first-ever drugs for the autoimmune disorder.

Led by Peter Kim, the method combines a ChatGPT-like large language model with information about a protein’s 3D shape and could lead to faster, more effective medicines.

Stanley Qi and team found that an RNA-targeting CRISPR platform could potentially unveil a relatively low-risk way to advance cell therapies for cancer.

Polly Fordyce and team found that highly repetitive regions of junk DNA may be the key to a newly discovered mechanism for gene regulation.

Charlotte Bravo (Chemistry ’25), Andrew Yang (Bioengineering & Electrical Engineering, ‘25), and Martin Hoberman (Biology ’25) support the development of anti-fungal drugs.